Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 1/20 | 0.51 |
| ▸ | FNTB | P49356 | 1/20 | 0.51 |
| ▸ | NAAA | Q02083 | 2/20 | 0.50 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.50 |
| ▸ | EPHX1 | P07099 | 8/20 | 0.47 |
| ▸ | METAP2 | P50579 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | RRM1 | P23921 | 1/20 | 0.46 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.44 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.44 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.44 |
| ▸ | MMP8 | P22894 | 1/20 | 0.44 |
| ▸ | CASP2 | P42575 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27658905 | 1.00 | FNTA (0.51) | FNTAFNTBNAAADPP7EPHX1 | |
| SCHEMBL20875833 | 0.98 | FNTA (0.54) | FNTAFNTBNAAADPP7EPHX1 | |
| SCHEMBL20875815 | 0.98 | FNTA (0.54) | FNTAFNTBNAAADPP7EPHX1 | |
| SCHEMBL20875810 | 0.98 | FNTA (0.54) | FNTAFNTBNAAADPP7EPHX1 | |
| SCHEMBL20875820 | 0.98 | FNTA (0.54) | FNTAFNTBNAAADPP7EPHX1 | |
| SCHEMBL20875764 | 0.98 | FNTA (0.54) | FNTAFNTBNAAADPP7EPHX1 | |
| SCHEMBL20875838 | 0.98 | FNTA (0.54) | FNTAFNTBNAAADPP7EPHX1 | |
| SCHEMBL20875781 | 0.98 | FNTA (0.54) | FNTAFNTBNAAADPP7EPHX1 | |
| SCHEMBL20875821 | 0.98 | FNTA (0.54) | FNTAFNTBNAAADPP7EPHX1 | |
| SCHEMBL20875835 | 0.98 | FNTA (0.54) | FNTAFNTBNAAADPP7EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11208392-B2 | N-alkyl-D-glucaro-6 amide derivatives and alkylammonium salts thereof as intermediates for preparing D-glucaro-6,3-lactone monoamide | BASF SE (DE) | 2021-12-28 | — | — | US | disclosed |
| US-20200277269-A1 | N-ALKYL-D-GLUCARO-6 AMIDE DERIVATIVES AND ALKYLAMMONIUM SALTS THEREOF AS INTERMEDIATES FOR PREPARING D-GLUCARO-6,3-LACTONE MONOAMIDE | BASF SE (DE) | 2020-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11208392-B2 | N-alkyl-D-glucaro-6 amide derivatives and alkylammonium salts thereof as intermediates for preparing D-glucaro-6,3-lactone monoamide | FUT6, MGAT3, GYPA | FNTA 1339/4885FNTB 3122/4885NAAA 52/4885 |
| US-20200277269-A1 | N-ALKYL-D-GLUCARO-6 AMIDE DERIVATIVES AND ALKYLAMMONIUM SALTS THEREOF AS INTERMEDIATES FOR PREPARING D-GLUCARO-6,3-LACTONE MONOAMIDE | FUT6, MGAT3, GYPA | FNTA 1339/4885FNTB 3122/4885NAAA 52/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.